Basel Medical Group Ltd Financials
This page shows Basel Medical Group Ltd (BMGL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Basel Medical Group Ltd carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.
Basel Medical Group Ltd's current ratio of 1.31 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 21/100, which could limit financial flexibility.
While Basel Medical Group Ltd generated -$3.2M in operating cash flow, capex of $438K consumed most of it, leaving -$3.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Basel Medical Group Ltd generates a -195.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
For every $1 of reported earnings, Basel Medical Group Ltd generates $0.38 in operating cash flow (-$3.2M OCF vs -$8.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Basel Medical Group Ltd generated $8.9M in revenue in fiscal year 2025.
Basel Medical Group Ltd reported -$8.4M in net income in fiscal year 2025.
Cash & Balance Sheet
Basel Medical Group Ltd generated -$3.6M in free cash flow in fiscal year 2025, representing cash available after capex.
Basel Medical Group Ltd held $2.4M in cash against $2.3M in long-term debt as of fiscal year 2025.
Basel Medical Group Ltd had 19M shares outstanding in fiscal year 2025.
Margins & Returns
Basel Medical Group Ltd's net profit margin was -94.0% in fiscal year 2025, showing the share of revenue converted to profit.
Basel Medical Group Ltd's ROE was -195.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Basel Medical Group Ltd invested $438K in capex in fiscal year 2025, funding long-term assets and infrastructure.
BMGL Income Statement
| Metric | Q4'25 |
|---|---|
| Revenue | N/A |
| Cost of Revenue | N/A |
| Gross Profit | N/A |
| R&D Expenses | N/A |
| SG&A Expenses | N/A |
| Operating Income | N/A |
| Interest Expense | N/A |
| Income Tax | N/A |
| Net Income | N/A |
| EPS (Diluted) | N/A |
BMGL Balance Sheet
| Metric | Q4'25 |
|---|---|
| Total Assets | $14.7M |
| Current Assets | $10.5M |
| Cash & Equivalents | $2.4M |
| Inventory | $385K |
| Accounts Receivable | $7.5M |
| Goodwill | N/A |
| Total Liabilities | $10.4M |
| Current Liabilities | $8.0M |
| Long-Term Debt | $2.3M |
| Total Equity | $4.3M |
| Retained Earnings | -$2.7M |
BMGL Cash Flow Statement
| Metric | Q4'25 |
|---|---|
| Operating Cash Flow | N/A |
| Capital Expenditures | N/A |
| Free Cash Flow | N/A |
| Investing Cash Flow | N/A |
| Financing Cash Flow | N/A |
| Dividends Paid | N/A |
| Share Buybacks | N/A |
BMGL Financial Ratios
| Metric | Q4'25 |
|---|---|
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
| Return on Equity | N/A |
| Return on Assets | N/A |
| Current Ratio | 1.31 |
| Debt-to-Equity | 0.54 |
| FCF Margin | N/A |
Similar Companies
Frequently Asked Questions
What is Basel Medical Group Ltd's annual revenue?
Basel Medical Group Ltd (BMGL) reported $8.9M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Basel Medical Group Ltd profitable?
No, Basel Medical Group Ltd (BMGL) reported a net income of -$8.4M in fiscal year 2025, with a net profit margin of -94.0%.
How much debt does Basel Medical Group Ltd have?
As of fiscal year 2025, Basel Medical Group Ltd (BMGL) had $2.4M in cash and equivalents against $2.3M in long-term debt.
What is Basel Medical Group Ltd's net profit margin?
Basel Medical Group Ltd (BMGL) had a net profit margin of -94.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Basel Medical Group Ltd's return on equity (ROE)?
Basel Medical Group Ltd (BMGL) has a return on equity of -195.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Basel Medical Group Ltd's free cash flow?
Basel Medical Group Ltd (BMGL) generated -$3.6M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Basel Medical Group Ltd's operating cash flow?
Basel Medical Group Ltd (BMGL) generated -$3.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Basel Medical Group Ltd's total assets?
Basel Medical Group Ltd (BMGL) had $14.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Basel Medical Group Ltd's capital expenditures?
Basel Medical Group Ltd (BMGL) invested $438K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Basel Medical Group Ltd's current ratio?
Basel Medical Group Ltd (BMGL) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.
What is Basel Medical Group Ltd's debt-to-equity ratio?
Basel Medical Group Ltd (BMGL) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Basel Medical Group Ltd's return on assets (ROA)?
Basel Medical Group Ltd (BMGL) had a return on assets of -56.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Basel Medical Group Ltd's cash runway?
Based on fiscal year 2025 data, Basel Medical Group Ltd (BMGL) had $2.4M in cash against an annual operating cash burn of $3.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Basel Medical Group Ltd's earnings high quality?
Basel Medical Group Ltd (BMGL) has an earnings quality ratio of 0.38x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Basel Medical Group Ltd?
Basel Medical Group Ltd (BMGL) scores 28 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.